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Several specific mechanisms can be
envisioned for these quasi-linear do-
mains, which remarkably are distributed
near the radial paths of microtubules. Is
there a linear path cut through the actin-
bound membrane fences (Figure 1A)?
If so, the confinement width should
broaden when the cortical actin mesh-
work is disrupted. Do microtubules peel
the cortical actin away from the bilayer
and thus create a ‘‘tent’’ of actin-free
membrane (Figure 1B), or do they prefer-
entially localize to the well-known folds
of macrophages? This should be discern-
able in electron tomography. Is actin-
binding transmembrane protein (ABTP)
density spatially dependent on both actin
and tubulin (i.e., a scaffolded picket fence;
Figure 1C)? In this scaffolded picket fence
model, microtubules just below the
membrane could break the connections
between cortical actin and the ABTP
‘‘pickets’’ in the membrane, clearing a
path for diffusion of membrane compo-
nents along a channel but leaving the
cortical actin itself intact and still in
reasonable proximity to the membrane
for rapid reversal of tubulin-dependent
effects. Is the confinement zone itself
moving within the membrane, either by
diffusion or by attachment to one or
more molecular motors (Figure 1D)? Inthis case, the diffusion would be micro-
scopically isotropic with confinement to
190 nm, but a nanoscale drift in one di-
rection would be superimposed, as, for
example, in the Smoluchowski equation
(Berezhkovskii et al., 1989). There is pre-
cedence for the model of cytoskeletal
movement, such as in the radial actin mo-
toring in the immune synapse (Yu et al.,
2010). Further experiments will be neces-
sary to fully elucidate the mechanism
behind these domains.
The capabilities of superresolution mi-
croscopy and other single-molecule tech-
niques may be the key to understanding
how directed motion (for example via
actomyosin and microtubules) is cooper-
atively coupled to diffusive motion within
the bilayer. Simultaneous three-dimen-
sional superresolution live cell imaging of
actin, tubulin, and membrane compo-
nents, for example, could potentially dis-
tinguish directly between the models dis-
cussed here. The techniques used by
Jaqaman et al. to measure directly colli-
sion rates and metastable clustering ele-
gantly add the important fourth dimension
of protein-protein interaction missing
from most membrane domain studies.
Future studies using these techniques
will be needed to test the hypothesis
that the geometry per se of cytoskeletalCell 14confinement plays a significant physio-
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Cell-fate decisions are tightly linked to cellular energy status. In this issue, Yi et al. (2011) introduce
a mechanism by which Bcl-xL lowers the threshold for apoptosis by suppressing acetyl-CoA pro-
duction, which, in turn, suppresses the N-alpha-acetylation important for activation of the proapop-
totic protease caspase-2.A cell’s decision to die by apoptosis,
become quiescent, or proliferate is influ-
enced by the metabolic conditions of thecell and its surrounding tissue. Over the
past decade, multiple studies have estab-
lished direct links between these criticalcellular pathways. For example, when glu-
cose levels fluctuate, glucose-sensing
pathways transduce signals through the6, August 19, 2011 ª2011 Elsevier Inc. 503
Figure 1. Regulation of Apoptosis by Bcl-xL
In addition to directly blocking Bax/Bak oligomerization and cytochrome c
release from the mitochondria, Bcl-xL also lowers the levels of acetyl-CoA
(possibly due to an indirect effect upstream of acetyl-CoA), resulting in
decreasedN-alpha-acetylationofapoptoticmediatorssuchascaspase-2, -3, -9
and Bax. In the case of caspase-2, N-alpha-acetylation is critical for its activa-
tion.AKT kinase to alter the post-
translational modifications
and/or expression levels of
Bcl-2 family proteins (re-
viewed in Buchakjian and
Kornbluth, 2010). More chal-
lenging, given the vast array
of metabolites in the cell and
the tangledmetabolic circuitry
into which they feed, has
been the elucidation of inter-
actions between small-mole-
cule metabolites and cell-fate
signaling pathways. Yi et al.
(2011) now demonstrate that
the antiapoptotic potency of
Bcl-xL protein stems in part
from its ability to lower levels
of acetyl-CoA, a substrate of
protein acetyltransferases
(Figure 1). This results in the
decreased N-alpha-acetyla-tion of multiple apoptotic regulators,
including caspases and the proapoptotic
Bcl-2 family member Bax, thereby
increasing resistance to apoptotic stimuli.
Distinct enzymes control protein
N-terminal acetylation and the acetylation
of lysine residues. Lysine acetylation is
increasingly appreciated as a dynamic
signaling event, but the role of N-alpha-
acetylation has been more enigmatic.
N-alpha-acetylation is catalyzed by
N-terminal acetyltransferases (NATs—
comprising NatA through NatF in eukary-
otes) and is thought to aid in the proper
function, localization, and stabilization of
certain proteins (reviewed in Arnesen,
2011). However, N-alpha-acetylation is
considered irreversible, and early studies
showed that most eukaryotic proteins
have this modification, thus branding it
as a global modification required for
many proteins to function. The findings
of Yi et al. suggest that N-alpha-acetyla-
tion may have more nuanced and varied
biological roles.
Tomonitor protein N-alpha-acetylation,
the authors use a clever strategy that
involves subtiligase-mediated biotinyla-
tion and avidin capture of only those
proteins with free N termini. These exper-
iments reveal that the N-alpha-acetyla-
tion of apoptotic regulators is sensitive to
acute changes in the levels of acetyl-
CoA, suggesting that a cell’s threshold
for death is intimately linked, via thismodi-
fication, to nutrient status.504 Cell 146, August 19, 2011 ª2011 ElsevieThe idea that a posttranslational mod-
ification like N-alpha-aceytlation is regu-
lated by levels of the donor substrate,
acetyl-CoA, rather than by the enzymes
that catalyze the modification runs
counter to common wisdom concerning
other modifications like phosphorylation,
where the phosphoryl donor ATP is typi-
cally not limiting. Interestingly, a small
but growing body of literature suggests
that protein acetylation is indeed influ-
enced by fluctuating acetyl-CoA levels.
For example, glucose-mediated stimula-
tion of acetyl-CoA production via citrate/
ATP citrate lyase results in increased
histone acetylation and consequent tran-
scription of metabolic regulators (Wellen
et al., 2009). These observations and
those by Yi et al. imply that changes in
a single metabolite, acetyl-CoA, might
have a large ripple effect, altering tran-
scriptional pathways, metabolic circuits,
and apoptotic sensitivity.
Regulation of N-terminal acetylation
likely also occurs at the level of the acetyl-
transferases. Indeed, NAT complexes
show differing preferences for specific
N-terminal amino acid sequences (Arne-
sen, 2011). Furthermore, Yi et al. show
that RNAi-mediated ablation of ARD1,
a component of the NatA complex, sensi-
tizes cells to apoptosis and results in the
failure of a subset of apoptotic regulators
to be N-terminally acetylated. Therefore,
different NATs may target specific groups
of proteins. Thus, taking advantage ofr Inc.the subtiligase approach
developed by Yi et al. to iden-
tify the substrates of individual
NATs should be illuminating.
Bcl-xL’s antiapoptotic ef-
fect is generally attributed to
suppression of mitochondrial
cytochrome c release through
inhibition of Bax/Bak. How-
ever, more than a decade
ago, the Hardwick laboratory
showed that Bcl-xL mutants
unable to bind Bax/Bak still
retain up to 80% of their
antiapoptotic activity (Cheng
et al., 1996). Intriguingly, Yi
et al. show that these same
mutants suppress acetyl-CoA
levels, suggesting that altering
protein N-terminal acetylation
through modulation of this
metabolite might contributesignificantly to Bcl-xL’s antiapoptotic
activity.
Obviously, these data raise the ques-
tion of how Bcl-xL impacts acetyl-CoA
levels. Under glucose-replete conditions,
citrate, a product of the tricarboxylic
acid (TCA) cycle, exits the mitochondria
and is converted to acetyl-CoA by ATP
citrate lyase. Interestingly, Yi et al. show
that stimulating acetyl-CoA production,
by adding citrate to cell culture media,
sensitizes cells to doxorubicin-induced
death, whereas RNAi ablation of ATP
citrate lyase abrogates this effect. In
probing this further, Yi et al. find that
citrate levels are reduced in Bcl-xL-ex-
pressing cells. Therefore, Bcl-xL may
exert its effect on acetyl-CoA levels by in-
hibiting the production and/or export of
citrate. The authors suggest that Bcl-xL
might block citrate export from the
mitochondria by interacting with the
voltage-dependent anion channel
(VDAC) (Shimizu et al., 1999; Vander Hei-
den et al., 2001), a component of themito-
chondrial pore complex that can regulate
metabolite efflux. Bcl-xL expression can
also inhibit cell proliferation, which might
indirectly affect acetyl-CoA levels by
reducing TCA cycle activity. In this regard,
it is interesting to note that the cell-cycle-
delaying and antiapoptotic activities of
Bcl-xL cosegregate in Bcl-xLmutants (Ja-
numyan et al., 2003). Additionally, expres-
sion of Bcl-xL alters mitochondrial fusion/
fission dynamics (Sheridan et al., 2008),
which can impact mitochondrial metabo-
lism (reviewed in Zorzano et al., 2010).
In a variety of tumor types, Bcl-xL
expression is critical for cell survival and,
as such, is considered a promising thera-
peutic target. The work of Yi et al. raises
important issues regarding the targeting
of Bcl-xL and its signaling partners. For
example, in tumor cells where Bcl-xL is
highly expressed, how does lowering
acetyl-CoA levels affect the cell’s biosyn-
thetic needs, most notably for fatty-acid
synthesis? What effect does Bcl-xL have
on lysine acetylation, which also requires
acetyl-CoA and would likely impact meta-
bolic pathways in cancer? Although these
and other questions remain, Yi et al.
provide strong evidence for a simple andelegant mechanism by which the levels
of a single metabolite, acetyl-CoA, can
directly regulate a cell’s sensitivity to
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